stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(9.12) | (1.95) |
P/Operating CF |
(2.08) | (2.08) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(0.47) | (0.47) |
EV/FCF |
(0.46) | (0.46) |
Quick Ratio |
2.70 | 4.56 |
Current Ratio |
2.85 | 4.70 |
Net Debt/EBITDA |
0.97 | 2.08 |
Debt/Assets |
0.88% | 1.24% |
Debt/Equity |
0.00 | (0.01) |
Asset Turnover |
0.08 | 0.00 |
Operating CF/Net income |
0.80 | 0.55 |
Capex/Depreciation |
(0.34) | (0.35) |
Interest Coverage |
(206.92) | (92.98) |
| 47.51% | 0.00% | |
| (58.82%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(137.62%) | (59.62%) |
Average Days of Receivables |
0.00 | 5.49 |
Research and Development Expense of Revenue |
704.54% | 856.89% |
Selling, General and Administrative Expense of Revenue |
132.51% | 205.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
64.52% | 95.14% |
Graham Net Nets |
(1.71) | (1.71) |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(30.53%) | (30.53%) |
Free Cash Flow Yield |
(102.57%) | (102.57%) |
Revenue per Share |
0.97 | 0.64 |
Operating CF per Share |
(6.08) | (3.67) |
Capex per Share |
(0.11) | (0.11) |
Free Cash Flow per Share |
(6.19) | (3.78) |
Cash per Share |
6.73 | 12.31 |
Shareholders Equity per Share |
(18.68) | (13.54) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(18.68) | (13.54) |
Free Cash Flow |
(204.13) | (121.19) |
Working Capital |
152.16 | 320.87 |
Capital Expenditures |
(3.51) | (3.44) |
Net Current Asset Value |
(711.78) | (545.29) |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.11 | 0.17 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.36 | 0.26 |
Cash ROIC |
52.18% | 367.03% |
Accounts Receivable Turnover |
0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Average Payables |
4.75 | — |
Average Assets |
424.22 | — |
Average Common Equity |
(525.24) | — |
Columns are period end dates · fundamentals updated 26 Oct 2026